Our demonstration that inhibiting DNA-PKcs with NU7441 effectively counters both IFI16 induction and DCM progression in vivo highlights the potential utility of targeting DDR components as a therapeutic strategy 128, 129. This evidence concerns the gene PRKDC and familial dilated cardiomyopathy.